416 related articles for article (PubMed ID: 29707793)
1. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
2. Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration.
Ishii K; Matsuoka I; Sasaki T; Nishikawa K; Kanda H; Imai H; Hirokawa Y; Iguchi K; Arima K; Sugimura Y
J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31484364
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast-derived exosomal microRNA regulates NKX3-1 expression in androgen-sensitive, androgen receptor-dependent prostate cancer cells.
Matsuda C; Ishii K; Nakagawa Y; Shirai T; Sasaki T; Hirokawa YS; Iguchi K; Watanabe M
J Cell Biochem; 2023 Aug; 124(8):1135-1144. PubMed ID: 37334663
[TBL] [Abstract][Full Text] [Related]
4. Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells.
Ishii K; Mizokami A; Tsunoda T; Iguchi K; Kato M; Hori Y; Arima K; Namiki M; Sugimura Y
J Cell Biochem; 2011 Dec; 112(12):3604-11. PubMed ID: 21809373
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth.
Culig Z; Bartsch G; Hobisch A
Mol Cell Endocrinol; 2002 Nov; 197(1-2):231-8. PubMed ID: 12431817
[TBL] [Abstract][Full Text] [Related]
7. Stromal TGF-β signaling induces AR activation in prostate cancer.
Yang F; Chen Y; Shen T; Guo D; Dakhova O; Ittmann MM; Creighton CJ; Zhang Y; Dang TD; Rowley DR
Oncotarget; 2014 Nov; 5(21):10854-69. PubMed ID: 25333263
[TBL] [Abstract][Full Text] [Related]
8. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
9. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.
Cioni B; Nevedomskaya E; Melis MHM; van Burgsteden J; Stelloo S; Hodel E; Spinozzi D; de Jong J; van der Poel H; de Boer JP; Wessels LFA; Zwart W; Bergman AM
Mol Oncol; 2018 Aug; 12(8):1308-1323. PubMed ID: 29808619
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
11. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
[TBL] [Abstract][Full Text] [Related]
12. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
13. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.
Lin DL; Whitney MC; Yao Z; Keller ET
Clin Cancer Res; 2001 Jun; 7(6):1773-81. PubMed ID: 11410519
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
16. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
Weissenrieder JS; Reilly JE; Neighbors JD; Hohl RJ
Prostate; 2019 Jan; 79(1):21-30. PubMed ID: 30106164
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
20. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z
Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
